开通VIP，畅享免费电子书等14项超值服
首页
好书
留言交流
下载APP
联系客服
2024.06.09湖北
郑薇,刘强（中山大学孙逸仙纪念医院乳腺肿瘤中心，广东广州510120）
Year-endreviewofclinicalresearchprogressinbreastcancerin2023ZHENGWei,LIUQiang(BreastTumorCenter,SunYat-senMemorialHospital,SunYat-senUniversity,Guangzhou510120,China)
（在框内向上滑动手指即可浏览全部参考文献）
[1]VeronesiU,PaganelliG,GalimbertiV,etal.Sentinel-nodebiopsytoavoidaxillarydissectioninbreastcancerwithclinicallynegativelymph-nodes[J].Lancet,1997,349(9069):1864-1867.doi:10.1016/S0140-6736(97)01004-0.
[2]黄娅,陈洁.乳腺癌新辅助化疗后前哨淋巴结分析的研究进展[J].中国普通外科杂志,2022,31(5):658-667.doi:10.7659/j.issn.1005-6947.2022.05.011.
HuangY,ChenJ.Researchprogressinanalysisofsentinellymphnodesafterneoadjuvantchemotherapyforbreastcancer[J].ChinaJournalofGeneralSurgery,2022,31(5):658-667.doi:10.7659/j.issn.1005-6947.2022.05.011.
[3]GentiliniOD,BotteriE,SangalliC,etal.SentinellymphnodebiopsyvsNoaxillarysurgeryinpatientswithsmallbreastcancerandnegativeresultsonultrasonographyofaxillarylymphnodes:theSOUNDrandomizedclinicaltrial[J].JAMAOncol,2023,9(11):1557-1564.doi:10.1001/jamaoncol.2023.3759.
[4]KragDN,AndersonSJ,JulianTB,etal.Sentinel-lymph-noderesectioncomparedwithconventionalaxillary-lymph-nodedissectioninclinicallynode-negativepatientswithbreastcancer:overallsurvivalfindingsfromtheNSABPB-32randomisedphase3trial[J].LancetOncol,2010,11(10):927-933.doi:10.1016/S1470-2045(10)70207-2.
[5]HuangY,ZhengS,LinY.Accuracyandutilityofpreoperativeultrasound-guidedaxillarylymphnodebiopsyforinvasivebreastcancer:asystematicreviewandmeta-analysis[J].ComputIntellNeurosci,2022,2022:3307627.doi:10.1155/2022/3307627.
[6]ParkeDW2nd,ColemanAL,RichWL3rd,etal.ChoosingWisely:fiveideasthatphysiciansandpatientscandiscuss[J].Ophthalmology,2013,120(3):443-444.doi:10.1016/j.ophtha.2013.01.017.
[7]deBonifaceJ,TvedskovT,LeifB,etal.Recurrence-freesurvivalfollowingsentinelnode-positivebreastcancerwithoutcompletionaxillarylymphnodedissection-firstresultsfromtheinternationalrandomizedSENOMACtrial[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS02-06.
[8]GiulianoAE,BallmanKV,McCallL,etal.EffectofaxillarydissectionvsNoaxillarydissectionon10-yearoverallsurvivalamongwomenwithinvasivebreastcancerandsentinelnodemetastasis:theACOSOGZ0011(alliance)randomizedclinicaltrial[J].JAMA,2017,318(10):918-926.doi:10.1001/jama.2017.11470.
[9]BartelsSAL,DonkerM,PoncetC,etal.Radiotherapyorsurgeryoftheaxillaafterapositivesentinelnodeinbreastcancer:10-yearresultsoftherandomizedcontrolledEORTC10981-22023AMAROStrial[J].JClinOncol,2023,41(12):2159-2165.doi:10.1200/JCO.22.01565.
[10]ClasseJM,LoaecC,GimberguesP,etal.Sentinellymphnodebiopsywithoutaxillarylymphadenectomyafterneoadjuvantchemotherapyisaccurateandsafeforselectedpatients:theGANEA2study[J].BreastCancerResTreat,2019,173(2):343-352.doi:10.1007/s10549-018-5004-7.
[11]MontagnaG.ArenodalITCsafterneoadjuvantchemotherapyanindicationforaxillarydissectionTheOPBC05/EUBREAST-14R/ICAROstudy[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS02-02.
[12]SaxenaN,HartmanM,AzizR,etal.Prognosticvalueofaxillarylymphnodestatusafterneoadjuvantchemotherapy.Resultsfromamulticentrestudy[J].EurJCancer,2011,47(8):1186-1192.doi:10.1016/j.ejca.2010.12.009.
[13]KishanAU,McCloskeySA.Postmastectomyradiationtherapyafterneoadjuvantchemotherapy:reviewandinterpretationofavailabledata[J].TherAdvMedOncol,2016,8(1):85-97.doi:10.1177/1758834015617459.
[14]FowbleBL,EinckJP,KimDN,etal.RoleofpostmastectomyradiationafterneoadjuvantchemotherapyinstageⅡ-Ⅲbreastcancer[J].IntJRadiatOncolBiolPhys,2012,83(2):494-503.doi:10.1016/j.ijrobp.2012.01.068.
[15]MamounasEP.Loco-RegionalIrradiationinPatientswithBiopsy-provenAxillaryNodeInvolvementatPresentationWhoBecomePathologicallyNode-negativeAfterNeoadjuvantChemotherapy:PrimaryOutcomesofNRGOncology/NSABPB-51/RTOG1304[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS02-07.
[16]SungH,FerlayJ,SiegelRL,etal.Globalcancerstatistics2020:GLOBOCANestimatesofincidenceandmortalityworldwidefor36cancersin185countries[J].CACancerJClin,2021,71(3):209-249.doi:10.3322/caac.21660.
[17]SheffieldKM,PeacheyJR,MethodM,etal.Areal-worldUSstudyofrecurrencerisksusingcombinedclinicopathologicalfeaturesinHR-positive,HER2-negativeearlybreastcancer[J].FutureOncol,2022,18(21):2667-2682.doi:10.2217/fon-2022-0310.
[19]GoetzMP,TurnerN,SasanoH,etal.240MOPrognosticandpredictiveimpactofestrogen/progesteronereceptor(ER/PR),andKi-67expression:anexploratoryanalysisfromthemonarchEtrialinpatientswithhigh-risk,HR+,HER2-,earlybreastcancer(EBC)[J].AnnOncol,2023,34:S278-S279.doi:10.1016/j.annonc.2023.09.438.
[20]HortobagyiGN.Ribociclib(RIB)+nonsteroidalaromataseinhibitor(NSAI)asadjuvanttreatmentinpatientswithHR+/HER2earlybreastcancer:finalinvasivedisease–freesurvival(iDFS)analysisfromtheNATALEEtrial[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS03-03.
[21]vonMinckwitzG,UntchM,BlohmerJU,etal.Definitionandimpactofpathologiccompleteresponseonprognosisafterneoadjuvantchemotherapyinvariousintrinsicbreastcancersubtypes[J].JClinOncol,2012,30(15):1796-1804.doi:10.1200/JCO.2011.38.8595.
[22]CortazarP,ZhangLJ,UntchM,etal.Pathologicalcompleteresponseandlong-termclinicalbenefitinbreastcancer:theCTNeoBCpooledanalysis[J].Lancet,2014,384(9938):164-172.doi:10.1016/S0140-6736(13)62422-8.
[23]CardosoF,O’ShaughnessyJ,McArthurH,etal.Neoadjuvantpembrolizumaborplacebo+chemotherapy,followedbyadjuvantpembrolizumaborplaceboplusendocrinetherapyforearly-stagehigh-riskER+/HER2-breastcancer:resultsfromthephase3KEYNOTE-756study[J].EurJCancer,2024,200:113608.doi:10.1016/j.ejca.2024.113608.
[24]CuriglianoG.BiomarkerResultsinHigh-riskEstrogenReceptorPositive,HumanEpidermalGrowthFactorReceptor2NegativePrimaryBreastCancerFollowingNeoadjuvantChemotherapy±Nivolumab:anExploratoryAnalysisofCheckMate7FL[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS01-01.
[25]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.doi:10.3969/j.issn.1007-3969.2015.09.010.
BreastCancerProfessionalCommitteeoftheChineseAnti-CancerAssociation.GuidelinesandspecificationsfordiagnosisandtreatmentofbreastcancerofChinaAnti-CancerAssociation(2015edition)[J].ChinaOncology,2015,25(9):692-754.doi:10.3969/j.issn.1007-3969.2015.09.010.
[26]LiuMH,LiuHY,ChenJ.MechanismsoftheCDK4/6inhibitorpalbociclib(PD0332991)anditsfutureapplicationincancertreatment(Review)[J].OncolRep,2018,39(3):901-911.doi:10.3892/or.2018.6221.
[27]SonkeGS,VanOmmen-NijhofA,WortelboerN,etal.Primaryoutcomeofthephase3SONIAtrial(BOOG2017-03)[J].JClinOncol,2023,41(suppl17):LBA1000.doi:10.1200/JCO.2023.41.17_suppl.LBA1000.
[28]KalinskyK,AccordinoMK,ChiuzanC,etal.RandomizedphaseⅡtrialofendocrinetherapywithorwithoutribociclibafterprogressiononcyclin-dependentkinase4/6inhibitioninhormonereceptor-positive,humanepidermalgrowthfactorreceptor2-negativemetastaticbreastcancer:MAINTAINtrial[J].JClinOncol,2023,41(24):4004-4013.doi:10.1200/JCO.22.02392.
[29]Llombart-CussacA,Harper-WynneC,PerelloA,etal.Second-lineendocrinetherapy(ET)withorwithoutpalbociclib(P)maintenanceinpatients(pts)withhormonereceptor-positive(HR[+])/humanepidermalgrowthfactorreceptor2-negative(HER2[-])advancedbreastcancer(ABC):PALMIRAtrial[J].JClinOncol,2023,41(16_suppl):1001.doi:10.1200/JCO.2023.41.16_suppl.1001.
[30]ChauCH,SteegPS,FiggWD.Antibody-drugconjugatesforcancer[J].Lancet,2019,394(10200):793-804.doi:10.1016/S0140-6736(19)31774-X.
[31]WenY,OuyangDJ,ZouQY,etal.AliteraturereviewofthepromisingfutureofTROP2:apotentialdrugtherapytarget[J].AnnTranslMed,2022,10(24):1403.doi:10.21037/atm-22-5976.
[32]RugoHS,BardiaA,MarméF,etal.Overallsurvivalwithsacituzumabgovitecaninhormonereceptor-positiveandhumanepidermalgrowthfactorreceptor2-negativemetastaticbreastcancer(TROPiCS-02):arandomised,open-label,multicentre,phase3trial[J].Lancet,2023,402(10411):1423-1433.doi:10.1016/S0140-6736(23)01245-X.
[33]BardiaA,JhaveriK,ImSA,etal.Randomizedphase3studyofdatopotamabderuxtecanvschemotherapyforpatientswithpreviously-treatedinoperableormetastatichormonereceptor-positive,HER2-negativebreastcancer:ResultsfromTROPION-Breast01[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS02-01.
[34]BardiaA.Clinicaloutcomesbyagesubgroupsinthephase3TROPiCS-02studyofsacituzumabgovitecanvstreatmentofphysician’schoiceinHR+/HER2metastaticbreastcancer[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:PO5-21-09.
[35]BrufskyAM,DicklerMN.Estrogenreceptor-positivebreastcancer:exploitingsignalingpathwaysimplicatedinendocrineresistance[J].Oncologist,2018,23(5):528-539.doi:10.1634/theoncologist.2017-0423.
[36]MillerTW,BalkoJM,ArteagaCL.Phosphatidylinositol3-kinaseandantiestrogenresistanceinbreastcancer[J].JClinOncol,2011,29(33):4452-4461.doi:10.1200/JCO.2010.34.4879.
[37]LoRussoPM.InhibitionofthePI3K/AKT/mTORpathwayinsolidtumors[J].JClinOncol,2016,34(31):3803-3815.doi:10.1200/JCO.2014.59.0018.
[39]TurnerNC,OliveiraM,HowellSJ,etal.Capivasertibinhormonereceptor-positiveadvancedbreastcancer[J].NEnglJMed,2023,388(22):2058-2070.doi:10.1056/NEJMoa2214131.
[40]OliveiraM,RugoHS,HowellSJ,etal.187OCapivasertibandfulvestrantforpatients(pts)witharomataseinhibitor(AI)-resistantHR+/HER2-advancedbreastcancer(ABC):SubgroupanalysesfromthephaseⅢCAPItello-291trial[J].ESMOOpen,2023,8(1):101376.doi:10.1016/j.esmoop.2023.101376.
[41]程瑞,纪文鑫,周灿,等.HER2阳性乳腺癌新辅助治疗的热点问题与研究进展[J].中国普通外科杂志,2023,32(5):771-781.doi:10.7659/j.issn.1005-6947.2023.05.017.
ChengR,JiWX,ZhouC,etal.HottopicsandresearchadvancesinneoadjuvanttherapyforHER2positivebreastcancer[J].ChinaJournalofGeneralSurgery,2023,32(5):771-781.doi:10.7659/j.issn.1005-6947.2023.05.017.
[42]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会CSCO乳腺癌诊疗指南2023[M].北京:人民卫生出版社,2023.
ChineseSocietyofClinicalOncologyGuidelinesWorkingCommittee.ChineseSocietyofClinicalOncology(CSCO)GuidelinesfortheDiagnosisandTreatmentofBreastCancer(2023Edition)[M].Beijing:People'sMedicalPublishingHouse,2023.
[43]CortesJ,Perez-GarcaJM,Ruiz-BorregoM,etal.3-yearinvasivedisease-freesurvival(iDFS)ofthestrategy-based,randomizedphaseⅡPHERGaintrialevaluatingchemotherapy(CT)de-escalationinhumanepidermalgrowthfactorreceptor2-positive(HER2[+])earlybreastcancer(EBC)[J].JClinOncol,41(17_suppl):LBA506.doi:10.1200/JCO.2023.41.17_suppl.LBA506.
[44]GianniL,MunzoneE,MansuttiM,etal.Pathologiccompleteresponse(pCR)ofneoadjuvanttherapywithorwithoutatezolizumabinHER2-positive,earlyhigh-riskandlocallyadvancedbreastcancer:APTneoMichelangelorandomizedtrial[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:LBO1-02.
[45]MaF,YanM,LiW,etal.PyrotinibversusplaceboincombinationwithtrastuzumabanddocetaxelasfirstlinetreatmentinpatientswithHER2positivemetastaticbreastcancer(PHILA):randomised,doubleblind,multicentre,phase3trial[J].BMJ,2023,383:e076065.doi:10.1136/bmj-2023-076065.
[46]HurvitzS,LoiS,O'ShaughnessyJ,etal.HER2CLIMB-02:Randomized,Double-BlindPhase3TrialofTucatinibandTrastuzumabEmtansineforPreviouslyTreatedHER2-PositiveMetastaticBreastCancer[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS01-10.
[47]KropIE,WildiersH,HurvitzSA,etal.Anage-specificpooledanalysisoftrastuzumabderuxtecan(T-DXd)inpatients(pts)withHER2-positive(HER2+)metastaticbreastcancer(mBC)fromDESTINY-Breast01,-02,and-03[J].JClinOncol,2023,41(16_suppl):1006.doi:10.1200/jco.2023.41.16_suppl.1006.
[48]HurvitzSA,ModiS,LiW,etal.377OApooledanalysisoftrastuzumabderuxtecan(T-DXd)inpatients(pts)withHER2-positive(HER2+)metastaticbreastcancer(mBC)withbrainmetastases(BMs)fromDESTINY-Breast(DB)-01,-02,and-03[J].AnnOncol,2023,34:S335-S336.doi:10.1016/j.annonc.2023.09.554.
[49]MedirattaK,El-SahliS,D’CostaV,etal.Currentprogressesandchallengesofimmunotherapyintriple-negativebreastcancer[J].Cancers,2020,12(12):3529.doi:10.3390/cancers12123529.
[50]BarriosCH,HarbeckN,ZhangHA,etal.LBA1-Finalanalysisoftheplacebo-controlledrandomisedphase3IMpassion031trialevaluatingneoadjuvantatezolizumab(atezo)pluschemotherapy(CT)followedbyopen-labeladjuvantatezoinpatients(pts)withearly-stagetriple-negativebreastcancer(eTNBC)[J].AnnOncol,2023,8(1suppl_4):doi:101220.10.1016/esmoop/esmoop101220.
[51]SchmidP,AdamsS,RugoHS,etal.Atezolizumabandnab-paclitaxelinadvancedtriple-negativebreastcancer[J].NEnglJMed,2018,379(22):2108-2121.doi:10.1056/NEJMoa1809615.
[52]CortesJ,CesconDW,RugoHS,etal.Pembrolizumabpluschemotherapyversusplacebopluschemotherapyforpreviouslyuntreatedlocallyrecurrentinoperableormetastatictriple-negativebreastcancer(KEYNOTE-355):arandomised,placebo-controlled,double-blind,phase3clinicaltrial[J].Lancet,2020,396(10265):1817-1828.doi:10.1016/S0140-6736(20)32531-9.
[53]SchmidP,CortésJ,DentRA,etal.Pembrolizumaborplacebopluschemotherapyfollowedbypembrolizumaborplaceboforearly-stageTNBC:UpdatedEFSresultsfromthephaseⅢKEYNOTE-522study[C]//EuropeanSocietyofMedicalOncology.Madrid,Spain,2023ESMOAbstract:LBA18.
[54]BaileyAndrew,McArthurHeather,El-AbedSarra.etal.AddingatezolizumabtoadjuvantchemotherapyforstageⅡandⅢtriple-negativebreastcancerisunlikelytoimproveefficacy:interimanalysisoftheALEXANDRA/IMpassion030phase3trial[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS01-03.
[55]BouZerdanM,GhorayebT,SalibaF,etal.Triplenegativebreastcancer:updatesonclassificationandtreatmentin2021[J].Cancers,2022,14(5):1253.doi:10.3390/cancers14051253.
[56]FarmerH,McCabeN,LordCJ,etal.TargetingtheDNArepairdefectinBRCAmutantcellsasatherapeuticstrategy[J].Nature,2005,434(7035):917-921.doi:10.1038/nature03445.
[57]邵笛,余天剑,邵志敏.三阴性乳腺癌精准治疗研究进展[J].中国普通外科杂志,2023,32(11):1629-1638.doi:10.7659/j.issn.1005-6947.2023.11.001.
ShaoD,YuTJ,ShaoZM.Advancesinprecisiontreatmentoftriple-negativebreastcancer[J].ChinaJournalofGeneralSurgery,2023,32(11):1629-1638.doi:10.7659/j.issn.1005-6947.2023.11.001.
[58]PembrolizumabPlusOlaparibvsPembrolizumabPlusChemotherapyAfterInductionWithPembrolizumabPlusChemotherapyforLocallyRecurrentInoperableorMetastaticTNBC:Randomized,Open-Label,Phase2KEYLYNK-009Study[C]//SanAntonioBreastCancerSymposium.SANAntonio,Texas,2023SABCSAbstract:GS01-05.
[59]SchmidP,WysockiPJ,MaCX,etal.379MODatopotamabderuxtecan(Dato-DXd)+durvalumab(D)asfirst-line(1L)treatmentforunresectablelocallyadvanced/metastatictriple-negativebreastcancer(a/mTNBC):updatedresultsfromBEGONIA,aphaseⅠb/Ⅱstudy[J].AnnOncol,2023,34:S337.doi:10.1016/j.annonc.2023.09.556.